Healthcare Industry News:  Duchenne Muscular Dystrophy 

Biopharmaceuticals Cardiology Personnel

 News Release - April 7, 2016

PhaseBio Announces Leadership Team Appointments

John S. Lee, M.D., Ph.D., named Chief Medical Officer

John P. Sharp, CPA, named Chief Financial Officer

MALVERN, Pa., April 07, 2016 -- (Healthcare Sales & Marketing Network) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced the expansion of its leadership teams in Malvern, PA, and San Diego, CA, effective Monday, April 18. John S. Lee, M.D., Ph.D., has been appointed Chief Medical Officer and will be based at PhaseBio’s corporate headquarters in Malvern. John P. Sharp, CPA, has been named Chief Financial Officer and will be based in San Diego.

“Dr. Lee’s deep experience in translational research and clinical development will be invaluable to the clinical progression of our lead compounds and the identification of new therapeutic targets,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “In addition, we look forward to leveraging Mr. Sharp’s financial and business planning expertise as we explore strategic growth opportunities. We are thrilled to welcome Dr. Lee and Mr. Sharp to PhaseBio.”

Dr. Lee joins PhaseBio from Quintiles, where he served as Vice President & Global Head, Cardiovascular Center of Excellence. At Quintiles, Dr. Lee oversaw the growth of the company’s cardiovascular business, including leading drug development and product lifecycle management, and building external partnerships to accelerate drug development and clinical research. Prior to Quintiles, Dr. Lee was Executive Director, Head of Cardiovascular/Metabolic (CV/MET) Therapeutic Area at Bristol­Myers Squibb. Earlier in his career, Dr. Lee served as Medical Director at Merck & Co. Dr. Lee received an M.D. and a Ph.D. in biochemistry from Boston University School of Medicine, and a B.A. in biological sciences from Harvard University.

“PhaseBio’s unique ELP technology platform has generated a strong clinical pipeline of therapies that will provide less frequent dosing and better patient compliance,” said Dr. Lee. “I look forward to rapidly advancing these treatments to people in need and expanding the pipeline of ELP technology-based therapies.”

Mr. Sharp joins PhaseBio from HUYA Bioscience International, where he served as Chief Financial Officer. At HUYA, Mr. Sharp played a pivotal role in the company’s strategic direction, including evaluating licensing candidates, tax strategies and all financial activities. Prior to HUYA, Mr. Sharp was Chief Financial Officer at Ligand Pharmaceuticals where he oversaw accounting, treasury, tax and U.S. Securities and Exchange Commission reporting, as well as financial and operational due diligence on multiple asset and business acquisitions with an aggregate value of more than $140 million. Mr. Sharp received a B.S. in business administration with an emphasis in accounting from San Diego State University.

“PhaseBio’s strong leadership team, committed investor base and compelling technology platform has enabled the development of improved biologic drugs in orphan and blockbuster indications,” said Mr. Sharp. “I am excited to work with this impressive team to create multiple sources of value for investors.”

About PhaseBio

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel drugs to treat metabolic and specialty cardiopulmonary disorders. The Company's proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects. PhaseBio's lead development candidates include: PE0139, a novel, super-long-acting basal insulin-ELP fusion for once-weekly dosing; and PB1046, a weekly vasoactive intestinal peptide receptor agonist for the treatment of acute and chronic heart failure, the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy, Becker muscular dystrophy and X-linked dilated cardiomyopathy, and other indications. PhaseBio is privately owned with headquarters and research laboratories in Malvern, PA.

Source: PhaseBio Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.